1. Home
  2. VSTA vs CAPR Comparison

VSTA vs CAPR Comparison

Compare VSTA & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vasta Platform Limited

VSTA

Vasta Platform Limited

N/A

Current Price

$4.97

Market Cap

400.4M

Sector

Real Estate

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$28.93

Market Cap

324.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTA
CAPR
Founded
1966
2005
Country
Brazil
United States
Employees
1572
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
400.4M
324.6M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
VSTA
CAPR
Price
$4.97
$28.93
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$41.38
AVG Volume (30 Days)
9.0K
5.3M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.16
N/A
Revenue
$326,007,430.00
$11,130,509.00
Revenue This Year
$11.22
N/A
Revenue Next Year
$13.43
$16,329.74
P/E Ratio
$4.28
N/A
Revenue Growth
13.60
N/A
52 Week Low
$2.00
$4.30
52 Week High
$5.49
$40.37

Technical Indicators

Market Signals
Indicator
VSTA
CAPR
Relative Strength Index (RSI) 52.27 69.47
Support Level $4.92 $28.51
Resistance Level $4.99 $30.71
Average True Range (ATR) 0.10 1.53
MACD 0.00 -0.34
Stochastic Oscillator 93.33 64.75

Price Performance

Historical Comparison
VSTA
CAPR

About VSTA Vasta Platform Limited

Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: